Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Amgen challenges...

    Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-02T09:30:16+05:30  |  Updated On 16 Aug 2021 1:28 PM IST

    The IPR is seeking to invalidate new patents covering the composition of the main ingredient of Soliris, eculizumab, its formulation, and its use to treat blood disorder proxysmal nocturnal hemoglobinuria (PNH).


    U.S: The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris after Amgen Inc challenged them, court filings showed on Friday.


    The move deals a blow to Alexion's efforts to ward off competition for its top-selling drug, which accounted for nearly 82% of the drugmaker's total revenue in the latest quarter.


    Amgen is contesting the U.S. patents to Soliris that extend the drug's market exclusivity to 2027 from 2022.


    The Patent Trial and Appeal Board, an administrative court run by the U.S. patent office, said on Friday it was instituting an inter partes review (IPR) on the patents.


    The IPR is seeking to invalidate new patents covering the composition of the main ingredient of Soliris, eculizumab, its formulation, and its use to treat blood disorder proxysmal nocturnal hemoglobinuria (PNH).


    Soliris is approved for four indications and brought in sales of $980.8 million in the quarter ended June 30.


    Alexion said it will "vigorously defend" its patents and address the court's specific concerns in the IPR proceedings.


    The drugmaker is trying to retain its stronghold in the PNH market by converting patients to its Soliris-successor Ultomiris, which won U.S. approval last year.


    Alexion has also been seeking to expand labell for Soliris, which won U.S. approval to treat autoimmune disease neuromyelitis optical spectrum disorder (NMOSD) in June.


    Besides PNH and NMOSD, Soliris is approved for atypical hemolytic uremic syndrome and generalized myasthenia gravis (gMG).


    "Regardless of the ultimate outcome here, Soliris has orphan drug designation in the U.S. for gMG through late 2024 and for NMOSD through mid-2026," the company said.


    The U.S. Food and Drug Administration's Orphan drug status comes with incentives, including a period of marketing exclusivity, to developers of rare disease treatments.


    A decision on the validity of the new Soliris patients is expected in Q3 2020, as the U.S. patent office may require a full year for its assessment, SVB Leerink analyst Geoffrey Porges said.


    Analysts were expecting Alexion to prevail over Amgen in the United States, where Soliris raked in about 51% of its total sales in the last quarter.


    Amgen declined to comment on the court's decision to review Soliris patents.


    Alexion also awaits an impending European Patent Office (EPO) decision on its patent applications for Soliris, to extend the drug's PNH market exclusivity in the European Union to 2027.


    By Manas Mishra and Manojna Maddipatla


    Read Also: Amgen to pay hefty $13.4 billion for buying Celgene psoriasis drug Otezla

    AlexionAmgenautoimmune diseaseblood disorder treatmenteculizumabEPOEuropean Patent Officegeneralized myasthenia gravisGeoffrey PorgesIPRneuromyelitis optica spectrum disorderNMOSDPatent Trial and Appeal Boardpharmapharma companypharma newsPNHproxysmal nocturnal hemoglobinuriaSolirisSoliris successor Ultomiris
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok